(S (NP (JJ Early) (NN diagnosis)) (VP (VBZ is) (ADJP (JJ important)) (PP (IN for) (NP (NP (JJ type) (CD 2) (NNS diabetes)) (PRN (-LRB- -LRB-) (NP (NNP T2D)) (-RRB- -RRB-)))) (S (VP (TO to) (VP (VP (VB improve) (NP (NN patient) (NN prognosis))) (, ,) (VP (JJ prevent) (NP (NNS complications))) (CC and) (VP (VB reduce) (NP (JJ long-term) (NN treatment) (NNS costs))))))) (. .))
(S (NP (PRP We)) (VP (VBP present) (NP (NP (DT a) (NN novel) (NN risk) (VBG profiling) (NN approach)) (VP (VBN based) (PP (ADVP (RB exclusively)) (IN on) (NP (NP (NN health) (NN expenditure) (NNS data)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (ADJP (JJ available) (PP (TO to) (NP (JJ Belgian) (JJ mutual) (NN health) (NNS insurers)))))))))))) (. .))
(S (NP (PRP We)) (VP (VBD used) (NP (NP (NN expenditure) (NNS data)) (VP (VBN related) (PP (TO to) (NP (NP (NN drug) (NNS purchases)) (CC and) (NP (JJ medical) (NNS provisions)))))) (S (VP (TO to) (VP (VB construct) (NP (NP (NNS models)) (SBAR (WHNP (IN that)) (S (VP (VBP predict) (SBAR (IN whether) (S (NP (DT a) (NN patient)) (VP (MD will) (VP (VB start) (NP (JJ glucose-lowering) (NN pharmacotherapy)) (PP (IN in) (NP (DT the) (VBG coming) (NNS years))))))) (, ,) (PP (VBN based) (PP (IN on) (NP (NP (DT that) (NN patient) (POS 's)) (JJ recent) (JJ medical) (NN expenditure) (NN history)))))))))))) (. .))
(S (S (NP (NP (DT The) (NN design) (CC and) (NN implementation)) (PP (IN of) (NP (DT the) (NN modeling) (NN strategy)))) (VP (VBP are) (VP (VBN discussed) (PP (IN in) (NP (NN detail)))))) (CC and) (S (NP (JJ several) (NN learning) (NNS methods)) (VP (VBP are) (VP (VBN benchmarked) (PP (IN for) (NP (PRP$ our) (NN application)))))) (. .))
(S (NP (PRP$ Our) (ADJP (JJS best) (VBG performing)) (NN model)) (VP (NNS obtains) (NP (NP (ADJP (QP (IN between) (CD 74.9) (NN %) (CC and) (CD 76.8) (NN %))) (NP (NN area))) (PP (IN under) (NP (DT the) (NNP ROC) (NN curve))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (ADJP (JJ comparable) (PP (TO to) (NP (NP (JJ state-of-the-art) (NN risk) (NN prediction) (NNS approaches)) (PP (IN for) (NP (NNP T2D))) (VP (VBN based) (PP (IN on) (NP (NNS questionnaires)))))))))))) (. .))
(S (PP (IN In) (NP (NP (NN contrast)) (PP (TO to) (NP (JJ other) (NNS methods))))) (, ,) (NP (PRP$ our) (NN approach)) (VP (MD can) (VP (VB be) (VP (VBN implemented) (PP (IN on) (NP (DT a) (JJ population-wide) (NN scale))) (PP (IN at) (NP (ADJP (RB virtually) (DT no)) (JJ extra) (JJ operational) (NN cost)))))) (. .))
(S (ADVP (RB Possibly)) (, ,) (NP (PRP$ our) (NN approach)) (VP (MD can) (VP (VB be) (ADVP (RB further)) (VP (VBN improved) (PP (IN by) (NP (NP (JJ additional) (NN information)) (PP (IN about) (NP (NP (DT some) (NN risk) (NNS factors)) (PP (IN of) (NP (NNP T2D))))) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (JJ unavailable) (PP (IN in) (NP (NN health) (NN expenditure) (NNS data))))))))))) (. .))
